

13TH
EDITION

EMIRATES

HAEMATOLOGY CONFERENCE 2025
HOSTED BY EMIRATES SOCIETY OF HAEMATOLOGY

11-13
APRIL 2025

 **CONRAD DUBAI**
UNITED ARAB EMIRATES

PROGRAM



HOSTED BY

 **ESH**
شعبة الإمارات لأمراض الدم
Emirates Society of Haematology

FRIDAY, APRIL 11

PLENARY HALL

9:00 - 10:00	Registration	
10:00 - 11:30	Session 1: Nursing Workshop Moderator: Khaled Al Qawasmeh	
10:00 - 10:20	Welcome & Introduction	EOHNS Sumaya AlBlooshi - ENA President Asma Alblooshi - EOHNS President
10:20 - 10:40	Enasidenib in the treatment of mutant IDH2 acute myeloid leukemia	Amal Al Haddad
10:40 - 11:00	Coffee Break	
11:00 - 11:20	Fitusiran SC for hemophilia	Mahmoud Hasan
11:20 - 11:40	Management of Febrile Neutropenia	Alaa Alabbadi
11:40 - 11:50	Q&A	
11:50 - 12:50	Lunch Industry Symposia	
11:50 - 11:55	Express lunch pack will be served at the back of symposia hall	
11:55 - 12:25	Industry Symposium by Sandoz: Rixathon in NHL: What is new?	Amar Lal
12:25 - 12:55	Industry Symposium by Beigene: New innovative solutions in CLL management	Speaker: Hasan Al Yaseen Moderator: Mahmoud Marashi
12:55 - 13:10	Opening Remarks	Asma Sultan Al Olama
13:10 - 15:15	Session 2: Hemostasis & Thrombosis/ Hemoglobinopathies Moderators: Mozah AlMarshoodi & Sarah Sewaralthahab	
13:10 - 13:35	Novel Therapies in Immune Thrombocytopenia and Autoimmune Hemolytic Anemia	Hanny Al- Samkari
13:35 - 14:00	Disease modifying pharmacological therapies for sickle cell disease	Salam Al Kindi
14:00 - 14:25	Novel Therapies in Hereditary Hemorrhagic Telangiectasia	Hanny Al- Samkari
14:25 - 14:50	Acute chest syndrome; risk factors and management	Salam Al Kindi
14:50 - 15:15	Q&A - Meet the Experts	All Faculty
15:15 - 15:30	Coffee Break	

FRIDAY, APRIL 11

PLENARY HALL

15:30 - 16:50	Session 3: Challenging Cases/ Updates in Benign Hematology Moderators: Abdulhakim Al Rawas, Amna Al Mehairi & David Spence	
15:30 - 15:50	Nightmares and Needles: A Young Woman's Mysterious Pain	Mohamed Abuhaleeqa
15:50 - 16:10	Turning Tides in Thalassemia Management: Disease State - 2025 Onwards	Hany Dewedar
16:10 - 16:30	Updates on B Thalassemia	Amar Lal
16:30 - 16:50	Q&A - Meet the Experts	All Faculty

SATURDAY, APRIL 12

PLENARY HALL

8:00 - 9:00	Registration	
9:00 - 10:30	Session 4: Myeloma & Lymphoma - Part I Moderators: Mahmoud Marashi & Inas El Najjar	
9:00 - 9:20	AL amyloidosis- Recent advances in the diagnosis and management	Ashutosh Wechalekar
9:20 - 9:40	How I treat MCL in 2025, is there still a rule for transplant	Jeremy Abramson
9:40 - 10:00	Management of Smoldering Myeloma	Ashutosh Wechalekar
10:00 - 10:20	Management of High grade B-Cell lymphoma	Jeremy Abramson
10:20 - 10:30	Q&A - Meet the Experts	All Faculty
10:30 - 10:55	BTK inhibitors: Transforming first line therapy in Mantle cell lymphoma	Khalil Al Farsi
10:55 - 11:10	Coffee Break ☕	
11:10 - 11:35	Industry Symposium by GSK: A new era for treatment of Myelofibrosis patients	Amna Al Mehairi
11:35 - 12:00	Industry Symposium by AstraZeneca: Patient-centric care: a new era in PNH management	Speaker: Hani Osman Moderator: Husni Al Hateeti
12:00 - 14:05	Session 5: Myeloma & Lymphoma - Part II Moderators: Salem Alshemmari & Husni Al Hateeti	
12:00 - 12:20	The dream of curing Multiple Myeloma	Ashutosh Wechalekar
12:20 - 12:40	ESHL: Is it time for chemotherapy only or chemotherapy free regimens?	Ranjana Advani
12:40 - 13:25	Best of ASH in lymphoma	Ranjana Advani
13:25 - 13:45	Should all relapsed lymphomas go to CAR T or should they try bisects first?	Jeremy Abramson
13:45 - 14:05	Q&A - Meet the Experts	All Faculty

SATURDAY, APRIL 12

PLENARY HALL

14:05 - 15:20		Lunch Industry Symposia 	
14:05 - 14:10		Express lunch pack will be served at the back of symposia hall	
14:10 - 14:35		Industry Symposium by Novartis: SCSEMBLIX: Breaking a New Ground in the Early CML Management	Speakers: Amar Lal & Hani Osman Moderator: Mahmoud Marashi
14:35 - 15:00		Industry Symposium by GSK: BCMA-Targeting Agents in RMM	Speaker: Inas El Najjar Moderator: Mahmoud Marashi
15:00 - 15:25		Industry Symposium by AbbVie: The new horizon in DLBCL management	Speaker: Faraz Khan Moderator: Asma Sultan Al Olama
15:25 - 16:15		Session 6: Challenging Cases in Lymphoma, Plasma Cell Dyscrasia & AML Moderators: Rania Medhat Seliem, Arif Alam & Hassan Ghazal	
15:25 - 15:35		Case Presentation 1:	Ahd Hassan
15:35 - 15:45		Case Presentation 2: Acute fatty liver of pregnancy complicating classical Hodgkin lymphoma	Marwa Ahmed
15:45 - 15:55		Case Presentation 3: Recurrent bleeding Uncovering the diagnosis of Multiple Myeloma. A Case of Multiple Myeloma Complicated with Acquired Von Willebrand Factor Deficiency	Esraa Abdulla Ibrahim Ockba
15:55 - 16:05		Case Presentation 4: Acute panmyelosis with myelofibrosis: a rare hematologic challenge	Marwa Ahmed
16:05 - 16:15		Q&A	
16:15 - 16:30		Coffee Break 	
16:30 - 17:40		Advances in DLBCL Management Workshop by Roche	Chairperson: Asma Sultan Al Olama Moderator: Arif Alam International Expert: Jeremy Abramson
16:30 - 16:35		Opening Remarks: Introduction to the workshop and objectives Brief insights on the evolving landscape of DLBCL	Asma Sultan Al Olama Jeremy Abramson
16:35 - 17:05		Session 1: First-Line & First Relapse Patients Moderator: Arif Alam	
16:35 - 17:05		Topics: Screening, Diagnosis, and Treatment Plan for First-Line Patients Management Strategies for Patients with First Relapse	Panelists: Hani Osman, Husni Al Hateeti, Hasan Al Yaseen Syed Mansoor & Rania Medhat Seliem
17:05 - 17:35		Session 2: Heavily Pretreated Patients & Role of BIETs Moderator: Arif Alam	
17:05 - 17:35		Topics: Challenges in treating heavily pretreated DLBCL patients Emerging role of BIETs (Bispecific T-cell Engagers) in therapy Expert Insight: Global perspective on BIETs in relapsed/refractory DLBCL	Panelists: Nameer Al Saadawi, Panagiotis Kalogiannidis, Amar Lal, Syed Mansoor & Rania Medhat Seliem Jeremy Abramson
17:35 - 17:40		Closing Remarks: Key takeaways and future outlook	Arif Alam Asma Sultan Al Olama

SUNDAY, APRIL 13

PLENARY HALL

8:00 - 9:00		Registration	
9:00 - 10:00		Session 7: MDS, MPN and Leukemia - Part I Moderators: Emmanouil Manos Nikolousis & Amar Lal	
9:00 - 9:20		ICUS/CCUS & CHIP; diagnosis & Management	Valeria Santini
9:20 - 9:40		HMA+Ven+/-Targeted inhibitor for all AML vs Intensive induction with or without BMT	Aaron Logan
9:40 - 10:00		Management of ET in pregnancy	Naseema Gangat
10:00 - 11:20		Session 8: MDS, MPN and Leukemia - Part II Moderators: Ruba Taha & Mohamed Abuhaleeqa	
10:00 - 10:20		Personalizing MDS therapy	Valeria Santini
10:20 - 10:40		Management of Ph like ALL in 2025	Aaron Logan
10:40 - 11:00		CML treatment in 2025, short term & long term complications	Naseema Gangat
11:00 - 11:20		Q&A - Meet the Experts	All Faculty
11:20 - 11:35		Coffee Break 	
11:35 - 12:20		Session 9: Abstracts Session Moderators: Hani Osman & Hasan Al Yaseen	
11:35 - 11:42		The predictive value of BRCA mutation on survival of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of phase III randomized clinical trials	Mus'ab Mustafa
11:42 - 11:49		Unusual case of IgG mediated cold agglutinin syndrome in a patient with marginal zone lymphoma	Ahd Hassan
11:49 - 11:56		Assessing Bone Mineral Density in Sickle Cell Disease Patients and linking it to Admission Rates: A Prospective Uni-center Study	Rehab Al-Ansari
11:56 - 12:03		Challenging Case of Mantle Cell Lymphoma (MCL) Presenting in Leukemic Phase, with A.Fib, retinal hemorrhage & GI bleeding: Therapeutic Challenges	Marwa Ahmed
12:03 - 12:10		The role of catechins as natural iron chelator	Rafat Abdeldaem
12:10 - 12:20		Insights on sequencing BiTEs and Car-T cell therapy in relapsed/refractory multiple myeloma	Osama Zein Deen
12:20 - 13:35		Lunch Industry Symposia 	
12:20 - 12:25		Express lunch pack will be served at the back of symposia hall	
12:25 - 12:50		Industry Symposium by CSL Vifor: Optimizing Blood Health: Innovative Approaches to Iron Deficiency Management	Hasan Al Yaseen
12:50 - 13:15		Industry Symposium by Pfizer: The Role of Elranatamab in Relapsed and Refractory Multiple Myeloma	Amna Al Mehairi
13:15 - 13:40		Industry Symposium by Stemline: The Evolving Role of Selinexor as the Next Frontier in RRMM Management	Amar Lal
13:40 - 13:45		Closing Remarks	Asma Sultan Al Olama



meeting minds
EXPERTS